Literature DB >> 21469947

Role of novel terpenes in transcutaneous permeation of valsartan: effectiveness and mechanism of action.

Abdul Ahad1, Mohammed Aqil, Kanchan Kohli, Yasmin Sultana, Mohd Mujeeb, Asgar Ali.   

Abstract

CONTEXT: The greatest obstacle for transdermal delivery is the barrier property of the stratum corneum. Many approaches have been employed to breach the skin barrier; the most widely used one is that of chemical penetration enhancers. Of the penetration enhancers, terpenes are arguably the most highly advanced and proven category.
OBJECTIVE: The aim of this investigation was to study effectiveness and mechanism of seven novel terpenes, namely iso-eucalyptol, β-citronellene, valencene, rose oxide, safranal, lavandulol acetate, and prenol, as potential penetration enhancers for improved skin permeation of valsartan through rat skin and human cadaver skin (HCS) with reference to established terpene eucalyptol.
METHODS: Skin permeation studies were carried out using Automated Transdermal Diffusion Cell Sampling System (SFDC 6, LOGAN Instruments Corp., NJ) on rat skin and HCS. The mechanism of skin permeation enhancement of valsartan by terpenes treatment was evaluated by Fourier transform infrared spectroscopy (FT-IR) analysis, differential scanning calorimetry (DSC) thermogram, and histopathological examination. RESULTS AND DISCUSSION: Among all study enhancers, iso-eucalyptol produced the maximum enhancement via rat skin [enhancement ratio (ER) = 7.4] and HCS (ER = 3.60) over control. FT-IR spectra and DSC thermogram of skin treated with aforesaid terpenes indicated that permeation occurred due to the disruption of lipid bilayers. No apparent skin irritation (erythema, edema) was observed on treatment with terpenes except β-citronellene, safranal, lavandulol acetate, and prenol, which caused mild irritation.
CONCLUSION: It is concluded that the iso-eucalyptol can be successfully used as safe and potential penetration enhancer for enhancement of skin permeation of lipophilic drug such as valsartan.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21469947     DOI: 10.3109/03639045.2010.532219

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  7 in total

1.  Formulation and Pharmacokinetic Evaluation of Polymeric Dispersions Containing Valsartan.

Authors:  Naveen Chella; Bhaskar Daravath; Dinesh Kumar; Rama Rao Tadikonda
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-10       Impact factor: 2.441

2.  Investigation of effects of terpene skin penetration enhancers on stability and biological activity of lysozyme.

Authors:  Rahul M Varman; Somnath Singh
Journal:  AAPS PharmSciTech       Date:  2012-08-29       Impact factor: 3.246

3.  Optimization of valencene containing lipid vesicles for boosting the transungual delivery of itraconazole.

Authors:  Quamrul Hoda; Mohd Aqil; Abdul Ahad; Syed Sarim Imam; Arshiya Praveen; Abdul Qadir; Zeenat Iqbal
Journal:  3 Biotech       Date:  2021-02-22       Impact factor: 2.406

4.  Chemical Fingerprint Profiles and Pharmacodynamic Investigation for Quality Evaluation of Moxa Smoke by UHPLC in a Rat Model of Superficial Infection.

Authors:  Yanling Wang; Shengbing Wu; Leijing Chen; Guo Xu; Xiaoxiao Wang; Jie Wu; Bin Wang; Meiqi Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-31       Impact factor: 2.629

5.  Enhancing the Bioavailability and Efficacy of Vismodegib for the Control of Skin Cancer: In Vitro and In Vivo Studies.

Authors:  Heba F Salem; Amr Gamal; Haitham Saeed; Marwa Kamal; Alaa S Tulbah
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-21

6.  Investigating the Potential of Transdermal Delivery of Avanafil Using Vitamin E-TPGS Based Mixed Micelles Loaded Films.

Authors:  Abdullah A Alamoudi; Osama A A Ahmed; Khalid M El-Say
Journal:  Pharmaceutics       Date:  2021-05-17       Impact factor: 6.321

7.  Formulation and characterization of novel soft nanovesicles for enhanced transdermal delivery of eprosartan mesylate.

Authors:  Abdul Ahad; Abdulmohsen A Al-Saleh; Abdullah M Al-Mohizea; Fahad I Al-Jenoobi; Mohammad Raish; Alaa Eldeen B Yassin; Mohd Aftab Alam
Journal:  Saudi Pharm J       Date:  2017-02-02       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.